NASDAQ:GNMX - Aevi Genomic Medicine Stock Price, Forecast & News

Aevi Genomic Medicine trades on the NASDAQ under the ticker symbol "GNMX."

Aevi Genomic Medicine Inc (NASDAQ:GNMX) posted its quarterly earnings data on Thursday, November, 14th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter. View Aevi Genomic Medicine's Earnings History.

Aevi Genomic Medicine is scheduled to release their next quarterly earnings announcement on Friday, April 3rd 2020. View Earnings Estimates for Aevi Genomic Medicine.

Headlines about GNMX stock have trended somewhat positive this week, according to InfoTrie Sentiment. The research group identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Aevi Genomic Medicine earned a media sentiment score of 2.0 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Aevi Genomic Medicine.

Aevi Genomic Medicine saw a drop in short interest in January. As of January 15th, there was short interest totalling 263,200 shares, a drop of 14.4% from the December 31st total of 307,300 shares. Based on an average daily trading volume, of 1,290,000 shares, the days-to-cover ratio is presently 0.2 days. Approximately 0.5% of the company's stock are short sold. View Aevi Genomic Medicine's Current Options Chain.

Some companies that are related to Aevi Genomic Medicine include Pluristem Therapeutics (PSTI), Genocea Biosciences (GNCA), Curis (CRIS), Allena Pharmaceuticals (ALNA), Idera Pharmaceuticals (IDRA), INmune Bio (INMB), Organovo (ONVO), Neon Therapeutics (NTGN), Entera Bio (ENTX), BioCardia (BCDA), Outlook Therapeutics (OTLK), Vaxart (VXRT), aTyr Pharma (LIFE), CytRx (CYTR) and Genetic Technologies (GENE).

Based on aggregate information from My MarketBeat watchlists, some companies that other Aevi Genomic Medicine investors own include SCYNEXIS (SCYX), Immunomedics (IMMU), Rigel Pharmaceuticals (RIGL), Protalix Biotherapeutics (PLX), Biocept (BIOC), Novavax (NVAX), TransEnterix (TRXC), Catalyst Pharmaceuticals (CPRX), Exelixis (EXEL) and Lipocine (LPCN).

Shares of GNMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of GNMX stock can currently be purchased for approximately $0.19.

Aevi Genomic Medicine has a market capitalization of $14.61 million. The biotechnology company earns $-30,770,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. Aevi Genomic Medicine employs 14 workers across the globe.View Additional Information About Aevi Genomic Medicine.

The official website for Aevi Genomic Medicine is http://www.aevigenomics.com/.

Aevi Genomic Medicine's mailing address is 435 DEVON PARK DRIVE SUITE 715, WAYNE PA, 19087. The biotechnology company can be reached via phone at 610-254-4201 or via email at [email protected]